Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested

Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2009, Pages 534-539

  Zhang, Xiaoping ^a   Silkey, Mariabeth ^b   Schumacher, Marta ^c   Wang, Lei ^c   Raval, Hiral ^c   Caulfield, John P ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE BIOSCIENCE   (United States)

Author keywords

Baseline adjusted; Moxifloxacin; Predose baseline; Thorough QT QTc study (TQT study); Time matched baseline

Indexed keywords

MOXIFLOXACIN; PLACEBO;

ADULT; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; METHODOLOGY; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; QUINOLINES;

EID: 65449138704     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008330158     Document Type: Article

References (12)

1. US Food and Drug Administration. Ich E. 14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Washington, DC: US Food and Drug Administration; 2005.
2. Bazett H. An analysis of the time relationship to the electrocardiogram. Heart. 1920 ; 7: 353-367.
3. Fridericia L. Die systolen dauer im elektrokardiogramm bei normalen menschen und bei herzkranke. Acta Med Scand. 1920 ; 53: 469.
4. Malhotra BK, Glue P., Sweeney K., Anziano R., Mancuso J., Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007 ; 81: 377-385. (Pubitemid 46364489)
5. Ring A., Ritzhaupt KBM, Platz J. Some properties of different analyses in "thorough QT studies," compared using a QT study of tiotropium. http://www.gmds2006.de/Abstracts/269.pdf. Accessed July 20, 2008.
6. Hulhoven R., Rosillon D., Letiexhe M., Meeus MA, Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007 ; 63: 1011-1017. (Pubitemid 47561809)
7. Sarapa N., Nickens DJ, Raber SR, Reynolds RR, Amantea MA Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther. 2008 ; 83: 153-159.
8. Kubitza D., Mueck W., Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 2008 ; 31: 67-77.
9. US Food and Drug Administration. Briefing document- cardiovascular and renal drug products. NDA 21-287 [alfuzosin HCl extended release (ER)] indication: treatment of the signs and symptoms of benign prostatic hyperplasia. Applicant: Sanofi-Synthelabo, Inc. May 29, 2003. http://www.fda.gov/ohrms/ dockets/ac/03/briefing/3956B1-01-FDA-alfuzosin.htm. Accessed May 30, 2008.
10. Shah RR Drugs, QTc interval prolongation and final ICH E14 guidance. Drug Saf. 2005 ; 28: 1009-1028. (Pubitemid 40321767)
11. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005 ; 5: 1038-1047. (Pubitemid 41192363)
12. Bloomfield DM, Kost JT, Ghosh K., et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008 ; 84: 475-480.